Sarika S Deodhar
6PUBLICATIONS
4CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Oct 16, 2025
Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trial.Jacek C Szepietowski, Adam Reich, Steven R Feldman
|Jul 25, 2025
Efficacy and safety of the ustekinumab biosimilar, Bmab 1200, versus reference ustekinumab in moderate-to-severe plaque psoriasis: 28‑week results of the randomized, double-blind, Phase 3 STELLAR-2 study.Jacek C Szepietowski, Adam Reich, Steven R Feldman
|Jun 10, 2025
Multiple Switches Between Adalimumab-fkjp and Reference Adalimumab in Moderate-to-Severe Chronic Plaque Psoriasis: A Multicenter, Double-Blind, Parallel Group, Randomized Clinical Trial for Interchangeability.Sarika Deodhar, Subramanian Loganathan, Ramesh Kadadanamari Subbarama Reddy
|May 07, 2025
Pharmacokinetic equivalence and comparative safety, tolerability, and immunogenicity of Biocon's ustekinumab (Bmab-1200) with EU-approved and US-licensed reference ustekinumab in healthy subjects: results from the Study to Test pharmacokinetic BioEquivalence of BiosimiLar ustekinumab to SteLARa (STELLAR-1).Jonathan Ackroyd, Sarika S Deodhar, Subramanian Loganathan
|Apr 19, 2023
REcovery and SURvival of patients with moderate to severe acute REspiratory distress syndrome (ARDS) due to COVID-19: a multicenter, single-arm, Phase IV itolizumab Trial: RESURRECT.Raveendra Kr, Chirag Rathod, Rahul Darnule
Pageof 1